Data Providers · Clarivate
CDK inhibitor class safety) — Illustrates how OFF-X translational safety intelligence can assess whether ocular toxicity is a class effect of CDK inhibitors, using public clinical-hold disclosures as the example.
The customer is anonymised in Clarivate’s own case study — not withheld by us.
Clarivate owns Cortellis, the curated competitive-intelligence and pipeline-tracking platform standard in pharma portfolio-management teams.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Source
Published by Clarivate on its own site — read the original case study on clarivate.com ↗
More like this
Related use cases
- 01Evolved its commercial, marketing and customer-engagement strategy using Clarivate real-world data and analytics.
- 02Used Clarivate/Cortellis IP and business support to advance a blood test for early ovarian cancer detection toward commercialization.
- 03Used Clarivate asset/technology and IP valuation expertise to make informed investment decisions in breakthrough biotech and science innovations.
- 04Partnered with Clarivate Regulatory Intelligence Tracking Application (companion to Cortellis Regulatory Intelligence) to transform and streamline regulatory workflow.
- 05Used a Clarivate patient-journey-mapping framework to integrate patient centricity into its mature/mid-lifecycle brand strategy in Asia Pacific, improving patient outcomes and brand awareness.
- 06Used Clarivate's DialogML (with Dialog and Drug Safety Triager) to apply AI/NLP to detect Individual Case Safety Reports (ICSRs) in scientific literature more efficiently for pharmacovigilance.